Industry Experts

Gilad is currently the Director of Protein Analytics and Developability at AstraZeneca, where they lead the development and implementation of analytics and developability strategies for biologics. Their expertise spans antibody engineering and therapeutic development, beginning with a PhD at Tel Aviv University focused on investigating conformational changes in HIV gp120 using sensitive antibodies, followed by postdoctoral research at the National Cancer Institute designing advanced anti-cancer immunotoxins. Since joining AstraZeneca, Gilad has driven progress in biologics engineering and contributed to several pipeline projects, notably including the anti-SARS-CoV-2 antibodies EVUSHELD (AZD7442) and KAVIGALE (AZD3152).